Price (delayed)
$26.17
Market cap
$3.76B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.27
Enterprise value
$4.49B
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved
There are no recent dividends present for INSM.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.